Research output per year
Research output per year
Organization profile
Organization profile
At UT Health San Antonio MD Anderson Cancer Center, our patient-and-family-centered care means including those closest to the patient in all care and treatment decisions. This increased level of communication leads to deeper connections between the care teams and the patients, more satisfied patients and better outcomes. Our multidisciplinary approach to cancer care allows our teams to customize treatments according to each individual and their personal cancer journey.
As the only National Cancer Institute-designated cancer center in South Texas, we contributeto the rapid pace of discovering the underlying causes of and treatments for cancer—so that our patients have access to more than 200 clinical trials specifically focused on cancer right here in San Antonio. These clinical trials can provide treatment options for patients at every stage of their disease. Our ongoing commitment to research is part of our mission to advance cancer care for every patient, every day.
Fingerprint
Dive into the research topics where Mays Cancer Center is active. These topic labels come from the works of this organization's members. Together they form a unique fingerprint.
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Profiles
-
A novel regimen for pancreatic ductal adenocarcinoma targeting MEK, BCL-xL, and EGFR
Han, S., Tushoski-Alemán, G. W., Zhang, P., Zheng, G., Zhou, D., Huo, Z., Licht, J., George, T. J., Allegra, C., Trevino, J. G. & Hughes, S. J., Jan 2025, In: Neoplasia (United States). 59, 101070.Research output: Contribution to journal › Article › peer-review
Open Access -
Asian Society of Mastology (ASOMA) Guide for Management of Nipple Discharge
Lohani, K. R., Singh, D., Vaidhyakkaran, I., Dhar, A., Jatoi, I., Chintamani, Kumar, S. & Srivastava, A., 2025, (Accepted/In press) In: Indian Journal of Surgery.Research output: Contribution to journal › Review article › peer-review
-
Racial Differences in Systemic Immune Parameters in Individuals With Lung Cancer
von Itzstein, M. S., Liu, J., Mu-Mosley, H., Fattah, F., Park, J. Y., SoRelle, J. A., Farrar, J. D., Gwin, M. E., Hsiehchen, D., Gloria-McCutchen, Y., Wakeland, E. K., Cole, S., Bhalla, S., Kainthla, R., Puzanov, I., Switzer, B., Daniels, G. A., Zakharia, Y., Shaheen, M. & Zhang, J. & 2 others, , Jan 2025, In: JTO Clinical and Research Reports. 6, 1, 100751.Research output: Contribution to journal › Article › peer-review
Open Access
Datasets
-
FON-2022-0484 infographic - Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis
Harrison, C. N. (Creator), Gupta, V. K. (Creator), Gerds, A. T. (Creator), Rampal, R. (Creator), Verstovsek, S. (Creator), Talpaz, M. (Creator), Kiladjian, J.-J. (Creator), Mesa, R. (Creator), Kuykendall, A. T. (Creator), Vannucchi, A. M. (Creator), Palandri, F. (Creator), Grosicki, S. (Creator), Devos, T. (Creator), Jourdan, E. (Creator), Wondergem, M. J. (Creator), Al-Ali, H. K. (Creator), Buxhofer-Ausch, V. (Creator), Alvarez-Larrán, A. (Contributor), Patriarca, A. (Creator), Kremyanskaya, M. (Creator), Mead, A. J. (Creator), Akhani, S. (Creator), Sheikine, Y. (Creator), Colak, G. (Creator) & Mascarenhas, J. (Creator), Future Science Group, 2022
DOI: 10.25402/fon.21130774, https://tandf.figshare.com/articles/figure/FON-2022-0484_infographic_-_Phase_III_MANIFEST-2_pelabresib_ruxolitinib_vs_placebo_ruxolitinib_in_JAK_inhibitor_treatment-naive_myelofibrosis/21130774
Dataset
-
Impact of Myeloproliferative neoplasms on patients’ employment status and work productivity in the United States: results from the living with MPNs survey
Yu, J. (Creator), Parasuraman, S. (Creator), Paranagama, D. (Creator), Bai, A. (Creator), Naim, A. (Creator), Dubinski, D. (Creator) & Mesa, R. (Creator), Figshare, 2018
DOI: 10.6084/m9.figshare.c.4069745.v1, https://springernature.figshare.com/collections/Impact_of_Myeloproliferative_neoplasms_on_patients_employment_status_and_work_productivity_in_the_United_States_results_from_the_living_with_MPNs_survey/4069745/1
Dataset
-
FON-2022-0484 infographic - Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis
Harrison, C. N. (Creator), Gupta, V. K. (Creator), Gerds, A. T. (Creator), Rampal, R. (Creator), Verstovsek, S. (Creator), Talpaz, M. (Creator), Kiladjian, J.-J. (Creator), Mesa, R. (Creator), Kuykendall, A. T. (Creator), Vannucchi, A. M. (Creator), Palandri, F. (Creator), Grosicki, S. (Creator), Devos, T. (Creator), Jourdan, E. (Creator), Wondergem, M. J. (Creator), Al-Ali, H. K. (Creator), Buxhofer-Ausch, V. (Creator), Alvarez-Larrán, A. (Contributor), Patriarca, A. (Creator), Kremyanskaya, M. (Creator), Mead, A. J. (Creator), Akhani, S. (Creator), Sheikine, Y. (Creator), Colak, G. (Creator) & Mascarenhas, J. (Creator), Future Science Group, 2022
DOI: 10.25402/fon.21130774.v1, https://tandf.figshare.com/articles/figure/FON-2022-0484_infographic_-_Phase_III_MANIFEST-2_pelabresib_ruxolitinib_vs_placebo_ruxolitinib_in_JAK_inhibitor_treatment-naive_myelofibrosis/21130774/1
Dataset